Yes , the results are decent. Q-o-Q, good growth in EBITDA. This is in line with most of other pharma companies i am tracking. Indian pharma companies are showing good growth in EBITDA margin since q4’20. Few developments to watch:
- Commissioning of Combo-line for Oral Dissolving Films and Transdermal products, which was expected by July’20.
- Phase 1 of the Biologics manufacturing plant which was due to be commissioned in June’20.
- Bringing on board a strategic investor for its Biologics unit. Recently Biocon did bring investment of Rs 225 crore in its Biologics unit from Tata Capital Growth Fund, valuing the Biologics unit at USD 3.5 billion. The capabilities developed by Shilpa medicare in its Biologics unit and the valuation it gets is something to watch for. The money will strengthen the balance sheet and also fastrack the further development of its Biologics unit.
Company has started sharing Investor presentation since last 2 quarters, hope to have this quarter’s by next week.
Disclosure: Invested since 2015.